Shanghai Pharma announces restricted period for 2019 stock options

Shanghai Pharmaceuticals Holding Co. Ltd. has announced the restricted exercise period for the third tranche of its 2019 A-share stock option incentive plan's reserved stock options. The full third exercise period is set to run from February 8, 2025, to February 7, 2026.

Within this broader window, a specific restricted exercise period has been designated from December 22, 2025, to January 5, 2026. During this defined timeframe, all eligible incentive recipients will be restricted from exercising their stock options.

The company confirms it will promptly process all necessary applications with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, concerning the restricted exercise. This announcement aligns with the company's 2025 semi-annual equity distribution plan and relevant regulatory guidelines.